siRNA, Anti-CDC42BPG, 2'-F/2'-OMe/LNA/Ribo/Backbone-modified(CAT#: SIRGT41741WQ-2OMe)
The product SIRGT41741WQ-2OMe is a type of small interfering RNA (siRNA) that targets CDC42BPG gene and regulates the expression of gene. The siRNA interferes with the expression of CDC42BPG gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2ʹ-O-methyl (2'-OMe) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.
| Specifications | |
|---|---|
| NCBI RefSeq | NM_017525.2 |
| Alternative Names | DMPK2; HSMDPKIN; KAPPA-200; MRCKG; MRCKgamma |
| Related Diseases | Epidermolysis Bullosa Simplex, Dowling-Meara Type |
| Purification | HPLC |
| Sub Cat | Target | Species | Modification | Scale | |
|---|---|---|---|---|---|
| SIRGT42741WQ-2F | CDC42BPG | Human | 2ʹ-deoxy-2ʹ-fluoro (2'-F) | ||
| SIRGT44741WQ-LNA | CDC42BPG | Human | Locked Nucleic Acid (LNA) | ||
| SIRGT41741WQ-RB | CDC42BPG | Human | Ribo-modified | ||
| SIRGT42741WQ-BB | CDC42BPG | Human | Backbone-modified | ||
| SIRGT102508WQ-BB | Cdc42bpg | Mouse | Backbone-modified |
